Who is sponsoring NCT03819543?

NCT03819543 is sponsored by University of Manitoba.

What drugs are being tested in NCT03819543?

Interventions in NCT03819543: Transcranial Direct Current Stimulation.

What condition does NCT03819543 study?

NCT03819543 studies Status Epilepticus.

Is NCT03819543 still recruiting?

NCT03819543 is currently terminated. Last updated 16 February 2023.

Are results published for NCT03819543?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-02-16 · How we verify

NCT03819543: SURESTEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SURESTEP: Transcranial Direct Current Stimulation in Super Refractory Status Epilepticus

Terminated NA Results posted Last updated 16 February 2023

What this trial tests

NA trial testing Transcranial Direct Current Stimulation in Status Epilepticus in 10 participants. Terminated before completion.

Timeline

15 July 2019

Primary endpoint
30 November 2020

31 August 2021

Quick facts

Lead sponsor	University of Manitoba
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	15 July 2019
Primary completion	30 November 2020
Estimated completion	31 August 2021
Sites	1 location across Canada

Drugs / interventions tested

Transcranial Direct Current Stimulation

Conditions studied

Status Epilepticus — all drugs for Status Epilepticus →

Sponsor

University of Manitoba

Who can join

18 and older, any sex, with Status Epilepticus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Frequency of Epileptiform Activity, Per Patient-based Primary · Up to 3 hours per EEG recording

EEG epileptiform activity as defined in units of spikes per second for a given patient. Pre-stim compares spike rates during stimulation to before stimulation. Pre-post compares spike rates after stimulation to before stimulation.

Pre-Stim Change (Automated Counts)

Group	Value	95% CI
Transcranial Direct Current Stimulation	-45.9	-59 – -11.9

Pre-Stim Change (Human Counts)

Group	Value	95% CI
Transcranial Direct Current Stimulation	-51.6	-70.2 – -17.9

Pre-Post Change (Automated Counts)

Group	Value	95% CI
Transcranial Direct Current Stimulation	-18.3	-25.4 – -1.4

Pre-Post Change (Human Counts)

Group	Value	95% CI
Transcranial Direct Current Stimulation	-25.3	-42.6 – -15.5

Frequency of Epileptiform Activity, Per-session Based Secondary · Up to 3 hours per EEG recording

EEG epileptiform activity as defined in units of spikes per second for a given stimulation session. Pre-stim compares spike rates during stimulation to before stimulation. Pre-post compares spike rates after stimulation to before stimulation.

Pre-Stim Change (Automated Counts)

Group	Value	95% CI
Transcranial Direct Current Stimulation	-47.2	-76.8 – -16.7

Pre-Stim Change (Human Counts)

Group	Value	95% CI
Transcranial Direct Current Stimulation	-38.5	-79.7 – -4.7

Pre-Post Change (Automated Counts)

Group	Value	95% CI
Transcranial Direct Current Stimulation	-6.8	-48.7 – 21.5

Pre-Post Change (Human Counts)

Group	Value	95% CI
Transcranial Direct Current Stimulation	-21.8	-61.4 – 12.7

Sponsor's own description

The purpose of this study is to determine whether transcranial direct current stimulation affects super refractory status epilepticus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transcranial Direct Current Stimulation

Trials testing the same drug.

NCT07496645 — EFFECT OF ANODAL TRANSCRANIAL DIRECT CURRENT STIMULATION ON NAMING IN APHASIC PATIENTS WITH ACUTE ISCHEMIC STROKE · Phase 3 · not yet recruiting
NCT07395531 — Effect of Repetitive Bihemispheric Anodal Transcranial Direct Current Stimulation on Motor Function of Patients With Par · Phase 3 · not yet recruiting
NCT07212634 — Cerebellar Transcranial Direct Current Stimulation for Dysphagia After Supratentorial Stroke · NA · not yet recruiting
NCT07319143 — The Effect of Transcranial Direct Current Stimulation (tDCS) in Improving Emotion Health · NA · recruiting
NCT06039605 — Priming Expectations and Motor Learning With tDCS · NA · completed

Other recruiting trials for Status Epilepticus

Currently open trials in the same condition.

NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
NCT06194747 — Improving Status Epilepticus Treatment Times · NA · recruiting
NCT06017973 — The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus · NA · recruiting
NCT05851391 — buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest · Phase 2 · recruiting
NCT05839418 — Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status · recruiting

Other University of Manitoba trials

Trials by the same sponsor.

NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03819543 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 16 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03819543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing